Stockscreener 앱 받기
198.05
0.41%
-0.81
시장 영업 전:
198.02
-0.03
-0.02%
Abbvie Inc 주식(ABBV)의 최신 뉴스
AbbVie’s Drug Upadacitinib Shows Positive Phase 3 Results for Severe Alopecia Areata Treatment - Insider Monkey
AbbVie Secures FDA Approval to Expand Mavyret’s Label - MSN
AbbVie’s Upcoming Study on ABBV-932: What Investors Need to Know - TipRanks
AbbVie's $0.81B Volume Ranks 104th as Stock Falls 0.41% on Mixed Earnings and Analyst Upgrades - AInvest
AbbVie-Genmab cancer collab shows promising results - Crain's Chicago Business
Genmab/AbbVie’s Epkinly Likely To See Label Expansion After Phase III Win - insights.citeline.com
AbbVie Inc. (ABBV): A Bull Case Theory - MSN
AbbVie Inclusion In Medicare Drug Talks Fails To Justify Lawsuit, Court Rules - Benzinga
Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79% - Benzinga
AbbVie and Genmab’s Promising B-Cell Lymphoma Trial: A Potential Game-Changer? - The Globe and Mail
AbbVie and Genmab’s Promising Phase 3 Trial for Follicular Lymphoma - The Globe and Mail
AbbVie’s Immunotherapy Trial: A Potential Game-Changer for Advanced Solid Tumors - TipRanks
AbbVie’s Duodopa Study: A Deep Dive into Parkinson’s Treatment - TipRanks
AbbVie Advances Glaucoma Treatment with XEN63 Gel Stent Study - TipRanks
AbbVie’s Promising Phase 3 Study on Upadacitinib for Hidradenitis Suppurativa - TipRanks
AbbVie’s Skyrizi rises to the top for pharma TV ad impressions - Medical Marketing and Media
AbbVie’s upadacitinib holds potential to cement dominant place in alopecia areata - The Pharma Letter
Pfizer and AbbVie Collaborate on Promising Pediatric Antibiotic Study - TipRanks
AbbVie’s Top Executive Makes a Multi-Million Dollar Stock Sale - TipRanks
AbbVie’s Phase 3 Study on Lutikizumab: A Potential Game-Changer for Hidradenitis Suppurativa - TipRanks
AbbVie and Genmab’s Epcoritamab Trial: A Promising Update for B-Cell Lymphoma Treatment - TipRanks
AbbVie’s Promising Study on Etentamig for Multiple Myeloma: A Potential Game-Changer - TipRanks
XtalPi inks pact with Greg Verdine’s DoveTree; Regenxbio, AbbVie update deal - Endpoints News
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Castle Biosciences (CSTL) and Regeneron (REGN) - The Globe and Mail
United States Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Novartis, Abbvie, Johnson & Johnson, Merck, Pfizer, BMS, Sanofi, GSK, Takeda - Yahoo Finance
Saudi Arabia OTC Artificial Tears Market Forecast and - GlobeNewswire
Saudi Arabia OTC Artificial Tears Market Forecast and Company Analysis Report 2025-2033 Featuring AbbVie, Akorn, Alcon, Bausch Health, J&J, Nicox, Novartis, Santen Pharmaceutical, Sun Pharmaceutical - Yahoo Finance
RegenXBio and AbbVie Amend Collaboration Agreement - TipRanks
Analyst recommendations: Abbvie, Airbnb, AMD, Ebay, Disney… - MarketScreener
AbbVie's 123rd-Ranked $790M Trading Volume Contrasts with $2.1B Acquisition and $1.9B Licensing Deals in Oncology Expansion - AInvest
AbbVie and Genmab’s Promising Phase 3 Study for DLBCL Treatment - The Globe and Mail
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - sharewise.com
AbbVie Stock Climbs 0.69% on $820M Volume Ranked 114th as Profits Plunge 31% Amid Resilient Revenue Growth - AInvest
AbbVie’s Ubrogepant Study: A New Hope for Menstrual Migraine Relief - TipRanks
AbbVie’s ABBV-101 Study: Promising Developments in B-Cell Malignancy Treatment - TipRanks
AbbVie and Genmab’s Promising Phase 2 Trial for DLBCL Treatment - TipRanks
AbbVie and Genmab’s Promising New Approach to Follicular Lymphoma - TipRanks
AbbVie Stock Outlook: Is Wall Street Bullish or Bearish? - MSN
AbbVie Stock Outlook: Is Wall Street Bullish Or Bearish? - Barchart.com
AbbVie Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
AbbVie price readies to tackle important resistanceForecast today05-08-2025 - Economies.com
Allergan Aesthetics Unveils the New Faces of Natrelle® and Real Stories of Empowerment and Transparency - AbbVie News Center
Stock Analysis | Abbvie OutlookA Mixed Picture with Strong Fundamentals and Optimistic Analysts - AInvest
AbbVie (ABBV) Q2 2025 Earnings Call Transcript - Mitrade
AbbVie: Balancing Strong Earnings with Humira Challenges and External Risks - TipRanks
AbbVie Inc. stock rises Monday, still underperforms market - MarketWatch
AbbVie Inc. SEC 10-Q Report - TradingView
Layoff Tracker: Sirona Liquidates TFChem, Merck Will Cut 6,000 Employees - BioSpace
AbbVie’s Promising Study on ABBV-453 for Multiple Myeloma: A Potential Game-Changer - TipRanks
AbbVie Raises 2025 Outlook After Q2 Beat - The Motley Fool
AbbVie Raises 2025 Outlook After Q2 Beat - The Globe and Mail
How Did Skyrizi and Rinvoq Sales Contribute to AbbVie's Q2 Results? - The Globe and Mail
AbbVie reports encouraging data from Upadacitinib trial for alopecia areata - MSN
If You'd Invested $1,000 in AbbVie (ABBV) Stock 10 Years Ago, Here's How Much You'd Have Today - MSN
AbbVie's Q2 2025 Earnings Call: Unpacking Contradictions in Skyrizi Growth, Inventory Strategies, and Market Dynamics - AInvest
AbbVie Shines in Earnings Call with Strong Growth - The Globe and Mail
Key deals this week: Chart Industries, Northwind Midstream, AbbVie, Palo Alto Networks and more - Seeking Alpha
AbbVie’s Real-World Study on Parkinson’s Treatment: A Potential Game Changer - The Globe and Mail
AbbVie Reports Strong Q2 2025 Financial Results - The Globe and Mail
AbbVie Shares Surge 3.28% on Strong Q2 Results and Analyst Upgrades, Trading Volume Ranks in Top 500 by Daily Trading Volume - AInvest
Why AbbVie Stock Flew Higher on Friday - MSN
1.05%
자본화:
|
볼륨(24시간):